Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020.
Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012.
Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He started his career in the life sciences practice at Boston Consulting Group, a management consulting company.
Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.
What is Jeremy Bender's net worth?
The estimated net worth of Jeremy Bender is at least $866,021.48 as of February 18th, 2025. Mr. Bender owns 128,015 shares of Day One Biopharmaceuticals stock worth more than $866,021 as of May 8th. This net worth approximation does not reflect any other investments that Mr. Bender may own. Additionally, Mr. Bender receives a salary of $900,000.00 as CEO at Day One Biopharmaceuticals. Learn More about Jeremy Bender's net worth.
How old is Jeremy Bender?
What is Jeremy Bender's salary?
How do I contact Jeremy Bender?
The corporate mailing address for Mr. Bender and other Day One Biopharmaceuticals executives is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. Day One Biopharmaceuticals can also be reached via phone at 650-484-0899 and via email at hans@lifesciadvisors.com. Learn More on Jeremy Bender's contact information.
Has Jeremy Bender been buying or selling shares of Day One Biopharmaceuticals?
Jeremy Bender has not been actively trading shares of Day One Biopharmaceuticals over the course of the past ninety days. Most recently, Jeremy Bender sold 12,048 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a transaction totalling $144,094.08. Following the completion of the sale, the chief executive officer now directly owns 128,015 shares of the company's stock, valued at $1,531,059.40. Learn More on Jeremy Bender's trading history.
Who are Day One Biopharmaceuticals' active insiders?
Are insiders buying or selling shares of Day One Biopharmaceuticals?
During the last twelve months, insiders at the sold shares 19 times. They sold a total of 177,625 shares worth more than $2,563,738.23. The most recent insider tranaction occured on February, 18th when CFO Charles N York II sold 4,370 shares worth more than $52,265.20. Insiders at Day One Biopharmaceuticals own 6.2% of the company.
Learn More about insider trades at Day One Biopharmaceuticals. Information on this page was last updated on 2/18/2025.
